Stressor: Not described SCL-90 scores decreased significantly at the end of treatment (d = 1.24). A second study (Kramer et al., 2015) published from this data set investigated changes in depression scores and found a significant reduction from pre to post treatment (d = 0.69) Pharmacotherapy Depressive symptoms – Amodeo RCT Italian cancer 50% with Pharmacotherapy Intervention: Intervention: 2.5 m/g Hospital N = 30 et al. patients with adjustment titration of day increasing by Anxiety and (2011) depressive disorder with paroxetine (SSRI) 2.5m/g each third day Depression disorders depressed Control: until 10m/g was Scale (HADS) mood titration of reached day 8. Day 9 Montgomery Intervention: paroxetine (SSRI) dose was increased to Asberg Age: 59.9 15m/g day and on day Depression (11.7) Stressor: 11 the full 20m/g day Rating Scale Male: 27% Health dose was reached (MADRS) Control: 10m/g day Hamilton Control: and increased to Anxiety Age: 61.8 20m/g day on day 8 Rating (10.5) (HAM-A)
Stressor: Not described SCL-90 scores decreased significantly at the end of treatment (d = 1.24). A second study (Kramer et al., 2015) published from this data set investigated changes in depression scores and found a significant reduction from pre to post treatment (d = 0.69) Pharmacotherapy – Depressive symptoms Amodeo et al. (2011) RCT Italian cancer patients with depressive disorders Intervention: Age: 59.9 (11.7) Male: 27% Control: Age: 61.8 (10.5) 50% with adjustment disorder with depressed mood Stressor: Health Pharmacotherapy Intervention: titration of paroxetine (SSRI) Control: titration of paroxetine (SSRI) Intervention: 2.5 m/g day increasing by 2.5m/g each third day until 10m/g was reached day 8. Day 9 dose was increased to 15m/g day and on day 11 the full 20m/g day dose was reached Control: 10m/g day and increased to 20m/g day on day 8 Hospital Anxiety and Depression Scale (HADS) Montgomery Asberg Depression Rating Scale (MADRS) Hamilton Anxiety Rating (HAM-A) N = 30